Skip to content

Mechanisms Underlying Local and Systemic Effects of Massage

Mechanisms Underlying Local and Systemic Effects of Massage

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04131712
Enrollment
44
Registered
2019-10-18
Start date
2020-08-01
Completion date
2023-06-01
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Atrophy

Keywords

Massage, Muscle, Extracellular Vesicles, Atrophy

Brief summary

The purpose of this study is to determine whether massage can attenuate the loss of muscle mass in humans after a short period of disuse.

Detailed description

The loss of skeletal muscle mass is a common symptom associated with diseases such as cancer, AIDS, diabetes, and congestive heart failure, and with aging. Muscle atrophy is associated with poor disease prognosis and decreased quality of life and therefore, maintaining muscle size and reducing the loss of muscle during disuse atrophy is of vital significance. Mechanical stimulation of muscle, such as during resistance exercise, stimulates protein synthesis that increases muscle protein content, and muscle size. The investigators have shown that mechanical stimulation applied to skeletal muscle in the form of massage is an effective mechanotherapy in rats, since it leads to a shift in protein turnover favoring anabolism, attenuation of muscle loss and enhanced regrowth after disuse-induced atrophy. Whether the same positive effect of massage occurs in humans is currently unknown, but would be extremely beneficial for skeletal muscle and overall health in case where resistance exercise is contraindicated or not feasible. In addition to the direct anabolic effects on the massaged rat muscle, the investigators have shown an equally beneficial response on the homologous muscle in the contralateral non-massaged limb. This novel finding indicated the existence of indirect mechanisms that could have profound systemic effects beyond the massaged muscle. Extracellular vesicles (EVs) are lipid membrane-bound vesicles released from cells with the ability to modulate function of cells from which they are released, as well as in cells with which they fuse. As such EVs are likely mediators of the well-documented but poorly-understood effects of massage in humans on the brain and other organs, such as relief of pain, anxiety or depression or changes in immunity. Therefore, the goal of this proposal is to determine anabolic effects of massage in human muscle, and to identify whether EVs released with massage are candidates for beneficial effects of this mechanotherapy on muscle as well as other organs. In Aim 1 the investigators will address the following hypothesis: Massage acts as a mechanotherapy by attenuating muscle atrophy through a shift in protein biogenesis towards anabolism in humans. Using a novel massage device we will apply mechanical load to muscle undergoing atrophy through unilateral lower limb suspension and muscle size as well as protein synthesis and degradation will be determined. In Aim 2 the investigators will test the hypothesis that massage attenuates the loss of EVs during atrophy by enhancing EV biogenesis in muscle. The investigators will measure EVs and their miRNA cargo in the serum, and markers of EV biogenesis in muscle of human subjects from Aim 1. Results from this study will indicate not only whether mechanotherapy, such as massage, can attenuate atrophy and enhance anabolic processes during disuse, but also determine whether EVs are a candidate mechanism for the overall health benefits of massage.

Interventions

OTHERMassage

A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.

Sponsors

University of Oklahoma
CollaboratorOTHER
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
Esther Dupont-Versteegden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Primary outcome assessors are blinded to treatment.

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women 18-30 years of age. * All races and ethnic backgrounds. * Non-smoker and generally healthy.

Exclusion criteria

* Have a current lower extremity musculoskeletal injury or compromised musculoskeletal function that would not allow the safe use of crutches or a brace. * Previous lower extremity surgeries or injury. * Activities of daily living require long periods of standing or driving a manual transmission car. * Body mass index (BMI) under 27. * Evidence or signs and symptoms of metabolic syndrome or disorder (diagnosis of diabetes or insulin resistance, elevated BP, high fasting blood sugar, abnormal cholesterol or triglyceride levels). * Thyroid disorder. * Acute or chronic infections. * Use of systemic steroids, anabolic steroids, or growth hormone. * Chronic aspirin or NSAID use (unless it can be safely stopped prior to the biopsies), and any other use of an anticoagulant (e.g., Coumadin) or history of bleeding including history of hypo- or hyper-coagulation disorders. * Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure). * Any other condition or events considered exclusionary by the PI and/or physician, such as non-compliance. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Percent Change in Myofiber Cross Sectional Area (CSA).9 daysThe ability of massage to attenuate the atrophic response to disuse will be determined. Muscle biopsies of the vastus lateralis will be used to quantify myofiber cross-sectional area. The percent change in myofiber size between day 7 and day -2 was used. Calculation details: \[(day 7 CSA) - (day -2 CSA)/(day -2 CSA)\]\*100
Myofibrillar Protein Synthesis Rate (MyoKsyn).9 daysThe ability of massage to attenuate the atrophic response to disuse due to protein synthesis will be determined. Muscle biopsies of the vastus lateralis will be used to quantify protein synthesis rates.

Secondary

MeasureTime frameDescription
Percent Change in Serum Extracellular Vesicle Number (EV #).9 daysThe ability of massage to attenuate the loss in EV number will be determined. Serum will be used to quantify EV numbers. The percent change in EVs between day 7 and day -2 was used.
Percent Change in the Expression of Muscle Rab27b mRNA.9 daysThe ability of massage to attenuate the loss in Rab27b protein expression will be determined. Muscle biopsies of the vastus lateralis will be used to quantify muscle Rab27b expression. The percent change in muscle Rab27b expression between day 7 and day -2 was used.

Countries

United States

Participant flow

Recruitment details

Subjects were actively recruited from the University of Kentucky campus as well as from the surrounding Lexington community through local advertisement using IRB approved recruitment flyers or newspaper advertisement. Recruitment occurred between August of 2020 and May 2023. The COVID pandemic shut down research activities at the University of Kentucky for some time impacting recruitment. Thus, the PI decided to focus on randomization of immobilized groups

Pre-assignment details

Consent, inclusion/exclusion criteria checklist, participant characteristics such as height and weight, and pregnancy testing were conducted prior to randomization.

Participants by arm

ArmCount
Ambulatory Control
Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. Atrophy will not be induced and massage intervention will not be applied. Ambulatory groups will be recruited following the immobilized groups.
9
Ambulatory Massage
Following baseline assessments, participants will be randomized into the ambulatory group for the remainder of the study. No atrophy induction. Four massage treatments will be applied every other day until the end of the study. Ambulatory groups will be recruited following the immobilized groups. Massage: A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
0
Immobilization Control
Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Massage intervention will not be applied.
16
Immobilization Massage
Following baseline assessments, participants will be randomized into the unilateral lower limb suspension group undergoing atrophy for the remainder of the study. Four massage treatments will be applied every other day until the end of the study. Massage: A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
16
Total41

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyCOVID related0020
Overall StudyPI withdrawal, subject could not follow study schedule0010

Baseline characteristics

CharacteristicImmobilization MassageTotalAmbulatory ControlImmobilization Control
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
16 Participants41 Participants9 Participants16 Participants
Age, Continuous22.07 years
STANDARD_DEVIATION 3.77
22.46 years
STANDARD_DEVIATION 3.66
22.83 years
STANDARD_DEVIATION 3.31
22.64 years
STANDARD_DEVIATION 3.93
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants5 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants36 Participants8 Participants15 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants1 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants3 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
14 Participants37 Participants8 Participants15 Participants
Region of Enrollment
United States
16 participants41 participants9 participants16 participants
Sex: Female, Male
Female
12 Participants28 Participants4 Participants12 Participants
Sex: Female, Male
Male
4 Participants13 Participants5 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 00 / 160 / 16
other
Total, other adverse events
0 / 90 / 04 / 165 / 16
serious
Total, serious adverse events
0 / 90 / 00 / 160 / 16

Outcome results

Primary

Myofibrillar Protein Synthesis Rate (MyoKsyn).

The ability of massage to attenuate the atrophic response to disuse due to protein synthesis will be determined. Muscle biopsies of the vastus lateralis will be used to quantify protein synthesis rates.

Time frame: 9 days

Population: Participants were not randomized to the ambulatory massage group. For the immobilization control group, one biopsy specimen could not be accurately analyzed due to tissue quality.

ArmMeasureValue (MEAN)Dispersion
Ambulatory ControlMyofibrillar Protein Synthesis Rate (MyoKsyn).1.19 percentage of protein produced per dayStandard Deviation 0.25
Immobilization ControlMyofibrillar Protein Synthesis Rate (MyoKsyn).1.04 percentage of protein produced per dayStandard Deviation 0.31
Immobilization MassageMyofibrillar Protein Synthesis Rate (MyoKsyn).1.07 percentage of protein produced per dayStandard Deviation 0.29
Primary

Percent Change in Myofiber Cross Sectional Area (CSA).

The ability of massage to attenuate the atrophic response to disuse will be determined. Muscle biopsies of the vastus lateralis will be used to quantify myofiber cross-sectional area. The percent change in myofiber size between day 7 and day -2 was used. Calculation details: \[(day 7 CSA) - (day -2 CSA)/(day -2 CSA)\]\*100

Time frame: 9 days

Population: Only one biopsy post 9 days was taken in the ambulatory groups only and thus % change could not be calculated. For the immobilization control group, one biopsy specimen could not be accurately analyzed due to tissue quality.

ArmMeasureValue (MEAN)Dispersion
Immobilization ControlPercent Change in Myofiber Cross Sectional Area (CSA).-15.1 percent change from baselineStandard Deviation 5.1
Immobilization MassagePercent Change in Myofiber Cross Sectional Area (CSA).-13.4 percent change from baselineStandard Deviation 3
Secondary

Percent Change in Serum Extracellular Vesicle Number (EV #).

The ability of massage to attenuate the loss in EV number will be determined. Serum will be used to quantify EV numbers. The percent change in EVs between day 7 and day -2 was used.

Time frame: 9 days

Population: Data was not generated.

Secondary

Percent Change in the Expression of Muscle Rab27b mRNA.

The ability of massage to attenuate the loss in Rab27b protein expression will be determined. Muscle biopsies of the vastus lateralis will be used to quantify muscle Rab27b expression. The percent change in muscle Rab27b expression between day 7 and day -2 was used.

Time frame: 9 days

Population: Data was not generated.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026